Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and to Explore the Pharmacodynamics of CDP7657 Administered in Healthy Subjects and in SLE Patients.

NCT01093911 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01093911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01093911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalating Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity and to Explore the Pharmacodynamics of CDP7657 Administered in Healthy Subjects and in SLE Patients.
Lead sponsor
UCB Pharma
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
December 31, 2012
Enrollment
44 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, connective tissue disease, immune system diseases, lupus erythematosus, systemic, skin and connective tissue diseases